Condition: Breast Neoplasms · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2 * Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles * Metastatic means the cancer has spread to other parts of the body Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Southern Cancer Center (SCC) ( Site 8000) | Daphne, Alabama, United States | Recruiting |
| The University of Arizona Cancer Center - North Campus ( Site 0055) | Tucson, Arizona, United States | Recruiting |
| Los Angeles Hematology Oncology Medical Group ( Site 0026) | Los Angeles, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian ( Site 0025) | Newport Beach, California, United States | Recruiting |
| St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021) | Grand Junction, Colorado, United States | Recruiting |
| Medical Oncology Hematology Consultants (MOHC) ( Site 8002) | Newark, Delaware, United States | Recruiting |
| AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0024) | Altamonte Springs, Florida, United States | Recruiting |
| Comprehensive Hematology Oncology ( Site 0060) | St. Petersburg, Florida, United States | Recruiting |
| Baptist Health Lexington ( Site 0050) | Lexington, Kentucky, United States | Recruiting |
| Baptist Health Hamburg ( Site 0071) | Lexington, Kentucky, United States | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) | Hackensack, New Jersey, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 0033) | New Brunswick, New Jersey, United States | Recruiting |
+ 183 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07060807